TABLE 1.
BASELINE CHARACTERISTICS OF PATIENTS TREATED VERSUS NOT TREATED WITH IBUPROFEN
| Treated | Not Treated | P Value* | |
|---|---|---|---|
| Baseline age, mean ± SD (n) | 10.2 ± 3.2 (1,365) | 9.7 ± 3.6 (8,960) | <0.0001 |
| 6–12 yr, % | 78.6 | 77.8 | 0.52 |
| 13–18 yr, % | 21.4 | 22.2 | |
| Male, % | 49.3% | 53.3% | 0.006 |
| Baseline FEV1 percent predicted, mean ± SD (n) | 92.1 ± 15.7 (1,365) | 92.5 ± 16.7 (8,960) | 0.73 |
| 60–79%pred, % | 24.8 | 24.9 | 0.48 |
| 80–89%pred, % | 19.7 | 20.4 | |
| 90–99%pred, % | 24.2 | 22.3 | |
| ⩾100%pred, % | 31.4 | 31.4 | |
| Weight-for-age percentile, mean ± SD (n) | 36.5 ± 26.4 (1,365) | 36.2 ± 26.8 (8,956) | 0.47 |
| Pseudomonas Aeruginosa infection | |||
| Never infected, % | 13.0 | 27.1 | <0.0001 |
| Infected after baseline, % | 22.5 | 24.5 | |
| Always infected, % | 62.3 | 44.4 | |
| Unknown baseline, later positive, % | 2.1 | 4.0 | |
| Hospitalizations in prior year, mean ± SD (n) | 0.36 ± 0.82 (1,301) | 0.30 ± 0.74 (7,610) | 0.010 |
| Median annual income ($), mean ± SD (n) | 48,527 ± 17,909 (1,326) | 46,063 ± 16,633 (8,633) | <0.0001 |
| No or state/federal insurance only, % | 20.2 | 30.3 | <0.0001 |
| Inhaled tobramycin use | |||
| At baseline, % | 16.5 | 10.1 | <0.0001 |
| Ever during follow-up, % | 76.7 | 61.3 | <0.0001 |
| Dornase alfa use | |||
| At baseline, % | 50.9 | 39.4 | <0.0001 |
| Ever during follow-up, % | 79.2 | 69.9 | <0.0001 |
*
P values from Wilcoxon rank sum test or chi-square test.